Garuda - Garba Rujukan Digital

Article Per Year (5 Year)

All

The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy

jghe
Website

Published by The Indonesian Society for Digestive Endoscopy

ISSN : 14114801 EISSN : 23028181 DOI : -

Core Subject : Health,

Medicine & Pharmacology

The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy is an academic journal which has been published since 2000 and owned by 3 Societies: The Indonesian Society of Gastroenterology; Indonesian Association for the Study of the Liver; The Indonesian Society for Digestive Endoscopy. The aim of our journal is to advance knowledge in Gastroenterology, Hepatology, and Digestive Endoscopy fields. We welcome authors for original articles, review articles, and case reports in the fields of Gastroenterology, Hepatology, and Digestive Endoscopy.

Arjuna Subject : Kedokteran - Ilmu Pencernaan

Articles 771 Documents

11 12 13 14 15

Current Prevention and Management of Non Steroid Anti Inflammatory Drugs Associated Gastroenteropathy Fransiscus Ari; Dadang Makmun
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 15, No 3 (2014): VOLUME 15, NUMBER 3, December 2014
Publisher : The Indonesian Society for Digestive Endoscopy

Non-steroid anti-inflammatory drugs (NSAIDs) are the most frequently used drugs to treat inflammation and are used almost in the whole world. However, NSAID is one of the important causes of gastroenteropathy development. NSAIDs enteropathy is frequently undetected because most of them are asymptomatic and required sophisticated examinations to diagnose. Not only non-selective cyclo-oxygenases (COX) inhibitor that can cause NSAID gastropathy, but selective COX-2 inhibitors may also cause gastrointestinal complications. NSAID gastroenteropathy require further evaluation and it may differ between patients.Currently, there is no effective treatment available to treat gastrointestinal damage associated with NSAIDs administration. Identification of protective factors in gastrointestinal complication due to NSAIDs use is still a serious challenge. In this review, we will discuss the effect of NSAID administration towards gastrointestinal system, also the prevention and management strategies.Keywords: non-steroid anti-inflammatory drugs, gastroenteropathy, COX inhibitor, prevention, treatment

Survival COVID-19 in Adult Patients with Liver Cirrhosis Gita Aprilicia; Syahrizal Syarif; Kemal Fariz Kalista; Andri Sanityoso Sulaiman; Irsan Hasan; Cosmas Rinaldi A Lesmana; Juferdy Kurniawan; Chyntia Olivia Maurine Jasirwan; Saut Horas Hatoguan Nababan; Rino Alvani Gani
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 22, No 2 (2021): VOLUME 22, NUMBER 2, August 2021
Publisher : The Indonesian Society for Digestive Endoscopy

Background: COVID-19 is a disease caused by infection of SARS-CoV-2 virus which leads to mortality due to respiratory failure. The progression of COVID-19 is more severe in patients with pre-existence morbidities, including liver disease. Recently, a few studie showed that liver cirrhosis patients with COVID-19 had a higher risk of mortality rather than liver cirrhosis patients without COVID-19 infection. Nevertheless, the study of survival COVID-19 in a patient with underlying liver cirrhosis is still limited. The aim of this study is to evaluate the survival of COVID-19 in adult patients with liver cirrhosisMethod: An observational study in Cipto Mangunkusumo Hospital was conducted. Patients with underlying liver cirrhosis between March 2020-January 2021 with positive confirmation of COVID-19 were enrolled in this study. Liver cirrhosis patients without COVID-19 were enrolled as a comparison. Both liver cirrhosis patients with and without COVID-19 were follow up at the time of hospital admission until 30 days outcome. Kaplan Meier and a log-rank test were conducted to evaluate the comparison of survival rate in liver cirrhosis patients with and without COVID-19. Multivariate Cox Proportional Hazard was conducted to identify the independent risk factors related to survival.Results: There were 22 liver cirrhosis patients with COVID-19 and 116 liver cirrhosis patients included in this study. Presentation of gender and age similar both of them. Predominantly males with average age were 57 years ± 13,60 for cirrhosis with COVID-19 patients and 53 years ± 12,75 for without COVID-19. The survival rate of liver cirrhosis patients with COVID-19 lower than liver cirrhosis patients without COVID-19 (35.8% vs. 67.2%, p-value 0.001). Median survival of liver cirrhosis patients with COVID-19 was 4 days (95% CI: 1-8 days), while median survival of liver cirrhosis patients without COVID-19 couldn’t be reached since the survival rate of this group above 50%. Final model Cox PH showed that liver cirrhosis with COVID-19 (HR: 8.99; CI 95%: 4.55 – 17.80, p-value 0.001) and Child-Pugh class C (HR: 5.61; 95% CI: 2.76 – 11.40, p-value 0.001) were the independent risk factors associated with poor survival.Conclusion: The survival rate of liver cirrhosis patients with COVID-19 lower than liver cirrhosis patients without COVID-19. Liver cirrhosis with COVID-19 and Child-Pugh class C were associated with poor survival.

Success Rate of Liver Stiffness Measurement Using Transient Elastography in Non-alcoholic Fatty Liver Disease Patients with Obesity and Its Influencing Factors Edi Mulyana; Irsan Hasan; Marcellus Simadibrata; Hamzah Shatri
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 16, No 2 (2015): VOLUME 16, NUMBER 2, August 2015
Publisher : The Indonesian Society for Digestive Endoscopy

Background: Percentage of patients who had liver stiffness measurement failure using transient elastography varied between 2-10%; mainly caused by obesity. XL probe is expected to increase the success rate of liver stiffness measurement in patients with obesity. The objective of this study is to evaluate the success of liver stiffness measurement using M and XL probes and its influencing factors.Method: Patients who fulfilled the inclusion criteria were included in this study. Examination results were then analysed using statistical analysis unpaired t-test or Mann-Whitney and McNemar statistical tests.Results: From 92 NAFLD patients with obesity who were studied, the proportion of success in measuring liver stiffness using M probe was 57.6%, while that of XL probe was 88.0%. This difference was statistically significant (p 0.001). BMI, SCD, and thoracic circumference were associated with success in measuring liver stiffness using M probe, with p value of 0.007, 0.001, and 0.001 respectively. The results of Mann-Whitney statistical test revealed median value of BMI and SCD of patients who had liver stiffness measurement failure using M probe were 32.7 kg/m2 and 2.6 cm respectively. T-test results showed that the mean value of thoracic circumference of patients who had liver stiffness measurement failure using M probe was 97.8 cm.Conclusion: Proportion of success in measuring liver stiffness in NAFLD patients with obesity using XL probe was better compared to the M probe. BMI, SCD, and thoracic circumference were associated with the success of measuring liver stiffness using M probe. The same variables were not associated with XL probe.

Rifampicin-induced acute renal failure and hepatitis Deni Kriscahoyo
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 1, NUMBER 1, December 2000
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/112000%p

Rifampicin is a potent drug and is the main drug in the multidrugs therapy for lung tuberculosis. We know this drug can induce hepatitis and nephritis in hypersensitive patient. The diagnosis of drug induced hepatitis is based on the fact that the patient was not ill before using the drug and become ill after taking it. In most cases the patient will improve after its withdrawal. We report a patient suffered from hepatitis and acute renal failure after using rifampicin and whose symptoms disappeared after stopping this drug. Key words: rifampicin, acute renal failure, hepatitis

Portal Hypertensive Enteropathy in Liver Cirrhosis Marcellus Simadibrata; Vera Yuwono; FJW Ten Kate; GNJ Tytgat; Daldiyono Daldiyono; Laurentius Lesmana; Iwan Ariawan
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 7, ISSUE 3, December 2006
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/73200661-66

Background/Aim: Some studies found that portal hypertension cause complication such as portal hypertensive gastroenterocolopathy. This study was done to find any abnormalities in the small intestinal mucosa and villi of the portal hypertensive patients. Method: Thirty patients with liver cirrhosis, portal hypertension and esophageal varices between 2000 - 2001 were included in this study. A duodenoscopic examination was performed to determine any abnormalities. Biopsy specimens were taken from the descending part of duodenum and the duodenal bulb for histopathological examination. The findings were compared to 37 functional dyspepsia patients. Result: In the duodenal bulb and descending part of duodenum: the width of the villous of the portal hypertensive group was larger than the control (p 0.001), the diameter of the mucosal villous vessel was larger than in the control (p 0.001) and the thickness of the mucosal villous vessel wall was thicker than in the control (p 0.001). Conclusion: There were abnormalities of the mucosa in portal hypertensive enteropathy patients including the mucosal vessel diameter, wall thickness, number of goblet cells. Keywords: portal hypertensive enteropathy, liver cirrhosis

Association Between Patient Characteristics and Diet Profile with Kirsten rat sarcoma Kras and Neuroblastoma rat sarcoma (Nras) Gene Mutation in Colorectal Cancer Dedy Indra Praja; Helena Helena; Bogi Pratomo
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 20, No 1 (2019): VOLUME 20, NUMBER 1, April 2019
Publisher : The Indonesian Society for Digestive Endoscopy

Background: Colorectal cancer is the third most common cancer according to American Cancer Society. It is also the third most common cause of death in men and women in US. Colorectal cancer encompasses 5% of all cancer and 29% of gastrointestinal cancer with men and women ratio is about 3:1. More than 1/3 of colorectal cancer occur below the age of 45 years. Mutation in Kirsten rat sarcoma (KRAS) gene was found in 30-50% of colorectal cancer in which it was suggested to associated with increase proliferation and decrease apoptosis. This study aimed to analyze the association between diet profile and KRAS gene mutation.Method: This study was a cross sectional study. Data was collected from medical records of colorectal cancer patient in Dr. Saiful Anwar General Hospital, which included KRAS gene mutation analysis.Results: There were 12 subjetcs included in this study. Four subjects (33.3%) had gene mutation with 3 subjects (75%) had positive KRAS mutation and 1 subjects (25%) had positive Neuroblastoma rat sarcoma (NRAS) mutation. In non-mutation group, it had been found a higher frequency of green leaf vegetables diet, in comparison with mutation group (p = 0.023). There was positive correlation between green leaf vegetables diet with gene mutation.Conclusion: Mutation of KRAS and NRAS mutation in colorectal carcinoma were found in 33.3% of subjects. Data analysis showed positive association between low green leaf vegetables diet with KRAS and NRAS mutation.

Microscopic Colitis in Patients with Diarrhea of Unknown Etiology: Diagnosis and Treatment Jacobus Albertus
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 13, NUMBER 1, April 2012
Publisher : The Indonesian Society for Digestive Endoscopy

Chronic diarrhea is a common reason for referral to a gastroenterologist. Microscopic colitis (MC) is fairly common cause of chronic non-bloody diarrhea. Microscopic colitis which was previously regarded rare, now has emerged as a common cause of chronic diarrhea. The condition is characterized clinically by chronic non bloody diarrhea, a macroscopically normal or near-normal colonic mucosa, but microscopic examination of mucosal biopsies reveals diagnostic histopathological changes. Microscopic colitis mainly includes two diseases, collagenous colitis (CC) and lymphocytic colitis (LC). In CC the most characteristic feature is thickening of the sub-epithelial collagen layer (SCL) beneath the basal membrane intra-epithelial lymphocyte (IEL) infiltration although not asprominent as in LC. The diagnosis of LC relies on a characteristic increase of IELs, which exceeds 20 IEL/100 surface epithelial cells compared with 5 IEL/100 surface epithelial cells in normal colonic mucosa. Randomized controlled trials (RCTs) assessing therapies for microscopic colitis have been performed. A previously published review showed that budesonide was effective in producing both clinical and histological responses in patients with collagenous colitis. This review will focus on epidemiology, clinical features and treatment of MC. Keywords: chronic diarrhea, microscopic colitis, lymphocytic and collagenous colitis

Vaccination for Inflammatory Bowel Disease Patients Yunihastuti, Evy
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 23, No 1 (2022): VOLUME 23, NUMBER 1, April 2022
Publisher : The Indonesian Society for Digestive Endoscopy

Inflammatory bowel disease (IBD) patients have an increased rate of some vaccine-preventable infection during their course of disease. However, the coverage of vaccination is still low. Many physicians often do not feel comfortable or confidence offering vaccination to IBD patients. Vaccine effectiveness can be altered by the immune dysregulation condition and immunosuppressive therapy that IBD patients use. There are also some concerns about IBD flare after vaccination and potential adverse events related to live vaccines. Nonetheless, offering vaccines and obtaining vaccination history is necessary for health care maintenance of IBD patients, especially those using immunosuppressive therapy.

The Prevalence of Reflux Esophagitis in the Elderly and Its Associated Risk Factors Cosmas Rinaldi A Lesmana; Billy Angga; Levina S Pakasi; Waldemar Simanjuntak; Laurentius A Lesmana
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 17, No 2 (2016): VOLUME 17, NUMBER 2, August 2016
Publisher : The Indonesian Society for Digestive Endoscopy

Background: Reflux esophagitis is a common problem in the elderly. Compare to the Western Countries, esophageal cancer where reflux esophagitis is the most predominant risk factor is considered rare in Asia. Many other risk factors have not been well studied especially in most Asian countries. The objective of this study is to evaluate the presence of reflux esophagitis in elderly patients and its associated risk factors.Method: This was a cross-sectional study in elderly patients who underwent upper gastrointestinal endoscopy. Patients who received long-term proton pump inhibitor (PPI) therapy, suffered from gastrointestinal malignancies, recently receiving chemotherapy agents, diagnosed with cerebrovascular disease or Helicobacter pylori infection were excluded. Statistical analyses were performed using the SPSS software version 17.00 (SPSS Inc., Chicago, Illinois, USA).Results: A total of 238 elderly patients were enrolled. Patients’ mean age was 69.8 ± 6.8 years old. Reflux esophagitis was found in 22 (9.2%) patients. Several comorbidities were found in these patients, such as diabetes, hypertension, coronary artery disease, chronic kidney disease, and liver cirrhosis. The only factor that associated with reflux esophagitis was the presence of hiatus hernia esophagus (p = 0.038). However, reflux esophagitis seemed to be more found in the elderly patients who have history of reflux inducing drugs consumption without any proton pump inhibitor (PPI) protection.Conclusion: Reflux esophagitis is still a major problem in the elderly. The presence of hiatus hernia might give an important consideration of upper gastrointestinal endoscopy screening. However, it would be a debate matter with regards to the cost burden and the low risk of esophageal cancer in Asian countries.

The Efficacy of Trimethoprim-sulfamethoxazole Compared to Ciprofloxacin in The Treatment of Spontaneous Bacterial Peritonitis in Cirrhotic Patients with Ascites Syadra Bardiman Rasyad; Ahmar Kurniadi; Fuad Bakry Fauzi
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 3, NUMBER 3, December 2002
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/33200276-81

Background: The incidence of spontaneous bacterial peritonitis (SBP) is 7 to 23%, and the associated mortality rate is 25 to 40% (Rimola 1992). The aim of this study was to evaluate the efficacy of trimethoprim-sulfamethoxazole compared to ciprofloxacin in the treatment of SBP in cirrhotic patients with ascites. Materials and Method: This prospective randomized double blind study included 43 cirrhotic patients with ascites (25 males, 18 females, ages 23-75 years, one female patient died prior to laboratory evaluation) enrolled between May 1999 and June 2000, at the Department of Internal Medicine of Mohammad Hoesin General Hospital /the Medical Faculty of Sriwijaya University of Palembang, South Sumatera. Twenty-three patients (53.4%) with SBP were eligible for the study, all were randomized. Patients were divided into 2 groups (13 in group I, and 10 in group II), those receiving trimethoprim- sulfamethoxazole 960 mg once daily for 10 days and those receiving ciprofloxacin 1000 mg once daily for 10 days. Statistically, there was no significant difference in the characteristics of the 2 groups. Results: The incidence of SBP in our study was 53.4% (23 patients out of 43 cirrhotic patients with ascites). The Results of the study demonstrate that trimethoprim-sulfamethoxazole and ciprofloxacin are both effective (91.6% and 90%) in the treatment of SBP. There was a significant decrease in ascitic fluid PMN count after 10 days treatment with both of the drugs (p=0.001 and p=0.000). There was no statistically significant difference (t-test) between the two groups in decreasing the ascitic fluid PMN count after the treatment (p=0.664). Conclusion: Trimethoprim-sulfamethoxazole and ciprofloxacin has similar efficacy in the treatment of spontaneous bacterial peritonitis in cirrhotic patients with ascites. Keyword: Trimethoprim-sulfamethoxazole, ciprofloxacin, spontaneous bacterial peritonitis.

Page 13 of 78 | Total Record : 771

11 12 13 14 15

Filter by Year

2000 2025

Filter By Issues

All Issue Vol 26, No 2 (2025): VOLUME 26, NUMBER 2, AGUSTUS, 2025 Vol 26, No 1 (2025): VOLUME 26, NUMBER 1, April, 2025 Vol 25, No 3 (2024): VOLUME 25, NUMBER 3, December, 2024 Vol 25, No 2 (2024): VOLUME 25, NUMBER 2, August, 2024 Vol 25, No 1 (2024): VOLUME 25, NUMBER 1, April, 2024 Vol 24, No 3 (2023): VOLUME 24, NUMBER 3, December, 2023 Vol 24, No 2 (2023): VOLUME 24, NUMBER 2, August, 2023 Vol 24, No 1 (2023): VOLUME 24, NUMBER 1, April, 2023 Vol 23, No 3 (2022): VOLUME 23, NUMBER 3, December 2022 Vol 23, No 2 (2022): VOLUME 23, NUMBER 2, August 2022 Vol 23, No 1 (2022): VOLUME 23, NUMBER 1, April 2022 Vol 22, No 3 (2021): VOLUME 22, NUMBER 3, December 2021 Vol 22, No 2 (2021): VOLUME 22, NUMBER 2, August 2021 Vol 22, No 1 (2021): VOLUME 22, NUMBER 1, April 2021 Vol 21, No 3 (2020): VOLUME 21, NUMBER 3, December 2020 Vol 21, No 2 (2020): VOLUME 21, NUMBER 2, August 2020 Vol 21, No 1 (2020): VOLUME 21, NUMBER 1, April 2020 Vol 20, No 3 (2019): VOLUME 20, NUMBER 3, December 2019 Vol 20, No 2 (2019): VOLUME 20, NUMBER 2, August 2019 Vol 20, No 1 (2019): VOLUME 20, NUMBER 1, April 2019 Vol 19, No 3 (2018): VOLUME 19, NUMBER 3, December 2018 Vol 19, No 2 (2018): VOLUME 19, NUMBER 2, August 2018 Vol 19, No 1 (2018): VOLUME 19, NUMBER 1, April 2018 Vol 18, No 3 (2017): VOLUME 18, NUMBER 3, DECEMBER 2017 Vol 18, No 2 (2017): VOLUME 18, NUMBER 2, AUGUST 2017 Vol 18, No 1 (2017): VOLUME 18, NUMBER 1, April 2017 Vol 17, No 3 (2016): VOLUME 17, NUMBER 3, December 2016 Vol 17, No 2 (2016): VOLUME 17, NUMBER 2, August 2016 Vol 17, No 1 (2016): VOLUME 17, NUMBER 1, April 2016 Vol 16, No 3 (2015): VOLUME 16, NUMBER 3, December 2015 Vol 16, No 2 (2015): VOLUME 16, NUMBER 2, August 2015 Vol 16, No 1 (2015): VOLUME 16, NUMBER 1, April 2015 Vol 15, No 3 (2014): VOLUME 15, NUMBER 3, December 2014 Vol 15, No 2 (2014): VOLUME 15, NUMBER 2, August 2014 Vol 15, No 1 (2014): VOLUME 15, NUMBER 1, April 2014 VOLUME 14, NUMBER 3, December 2013 VOLUME 14, NUMBER 2, August 2013 VOLUME 14, NUMBER 1, April 2013 VOLUME 13, NUMBER 3, Desember 2012 VOLUME 13, NUMBER 2, August 2012 VOLUME 13, NUMBER 1, April 2012 VOLUME 12, NUMBER 3, December 2011 VOLUME 12, NUMBER 2, August 2011 VOLUME 12, NUMBER 1, April 2011 VOLUME 11, NUMBER 3, December 2010 VOLUME 11, NUMBER 2, August 2010 VOLUME 11, NUMBER 1, April 2010 VOLUME 10, NUMBER 3, December 2009 VOLUME 10, ISSUE 2, August 2009 VOLUME 10, ISSUE 1, April 2009 VOLUME 9, ISSUE 3, December 2008 VOLUME 9, ISSUE 2, August 2008 VOLUME 9, ISSUE 1, April 2008 VOLUME 8, ISSUE 3, December 2007 VOLUME 8 ISSUE 2 August 2007 VOLUME 8, ISSUE 1, April 2007 VOLUME 7, ISSUE 3, December 2006 VOLUME 7, ISSUE 2, August 2006 VOLUME 7, ISSUE 1, April 2006 VOLUME 6, ISSUE 3, December 2005 VOLUME 6, ISSUE 2, August 2005 VOLUME 6, ISSUE 1, April 2005 VOLUME 5, ISSUE 3, December 2004 VOLUME 5, ISSUE 2, August 2004 VOLUME 5, ISSUE 1, April 2004 VOLUME 4, ISSUE 3, December 2003 VOLUME 4, ISSUE 2, August 2003 VOLUME 4, NUMBER 1, April 2003 VOLUME 3, NUMBER 3, December 2002 VOLUME 3, NUMBER 2, August 2002 VOLUME 3, NUMBER 1, April 2002 VOLUME 2, NUMBER 3, December 2001 VOLUME 2, NUMBER 2, August 2001 VOLUME 2, NUMBER 1, April 2001 VOLUME 1, NUMBER 1, December 2000 More Issue

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name
Murdani Abdullah

Contact Email
ina.jghe@gmail.com

Phone
+6285891498517

Journal Mail Official
ina.jghe@gmail.com

Editorial Address
Divisi Gastroenterologi, Departemen Ilmu Penyakit Dalam, FKUI/RSUPN Dr. Cipto Mangunkusumo, Jl. Diponegoro No. 71 Jakarta 10430 Indonesia

Location
Kota adm. jakarta pusat,

Dki jakarta

INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name Murdani Abdullah

Contact Email ina.jghe@gmail.com

Phone +6285891498517

Journal Mail Official ina.jghe@gmail.com

Editorial Address Divisi Gastroenterologi, Departemen Ilmu Penyakit Dalam, FKUI/RSUPN Dr. Cipto Mangunkusumo, Jl. Diponegoro No. 71 Jakarta 10430 Indonesia

Location Kota adm. jakarta pusat, Dki jakarta INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Contact Name
Murdani Abdullah

Contact Email
ina.jghe@gmail.com

Phone
+6285891498517

Journal Mail Official
ina.jghe@gmail.com

Editorial Address
Divisi Gastroenterologi, Departemen Ilmu Penyakit Dalam, FKUI/RSUPN Dr. Cipto Mangunkusumo, Jl. Diponegoro No. 71 Jakarta 10430 Indonesia

Location
Kota adm. jakarta pusat,

Dki jakarta

INDONESIA